Five firms that were scheduled to publish their final offering price and volumes on Monday announced that they would delay plans for IPOs on the mainland, South China Morning Post reported. It is believed that their PE ratios exceed the market average. Jiangsu Aosaikang Pharmaceutical also put its listing on hold on Friday after its lofty offering price and high volume. On Sunday, the securities regulator announced that companies planning to price their offer shares at a higher PE level than their peers traded on the exchange must postpone subscriptions by three weeks and publish repeated risk warnings.
You must log in to post a comment.
Yes, I would like to receive emails from China Economic Review. (You can unsubscribe anytime)
Copyright © 2018 SinoMedia Group Limited All rights reserved